biostudies-literatureUnknown13(9)Drago L<h4>Objectives</h4>To evaluate the in vitro antimicrobial activity of TiAB, a compound based on silver-bound titanium dioxide, against clinical isolates from dermatological infections.<h4>Methods</h4>We tested 155 strains clinically isolated from ulcers and skin infections, including MRSA, ESBL-producing <i>Enterobacterales</i>, and <i>P. aeruginosa</i>. MIC and MBC values were determined using broth microdilution according to CLSI guidelines. Time-kill assays were performed at 0.5×, 1×, and 2× MIC. Median values were used to describe susceptibility profiles.<h4>Results</h4>TiAB exhibited strong bactericidal activity against Gram-negative bacteria, including ESBL-positive <i>E. coli</i> and <i>K. pneumoniae</i>, with complete killing at 2× MIC (4-8%) within 4-8 h. Gram-positive pathogens eDiseases (Basel, Switzerland)277https://www.ebi.ac.uk/biostudies/studies/S-EPMC12468273biostudies-literatureIn Vitro Activity of Silver-Bound Titanium Dioxide (Tiab) Against Multidrug-Resistant Bacteria from Dermatological Infections.PMC12468273Drago LDeflorio LMinasi VUslenghi ACovi MDe La Motte LRGiarritiello FfalseIn Vitro Activity of Silver-Bound Titanium Dioxide (Tiab) Against Multidrug-Resistant Bacteria from Dermatological Infections.<h4>Objectives</h4>To evaluate the in vitro antimicrobial activity of TiAB, a compound based on silver-bound titanium dioxide, against clinical isolates from dermatological infections.<h4>Methods</h4>We tested 155 strains clinically isolated from ulcers and skin infections, including MRSA, ESBL-producing <i>Enterobacterales</i>, and <i>P. aeruginosa</i>. MIC and MBC values were determined using broth microdilution according to CLSI guidelines. Time-kill assays were performed at 0.5×, 1×, and 2× MIC. Median values were used to describe susceptibility profiles.<h4>Results</h4>TiAB exhibited strong bactericidal activity against Gram-negative bacteria, including ESBL-positive <i>E. coli</i> and <i>K. pneumoniae</i>, with complete killing at 2× MIC (4-8%) within 4-8 h. Gram-positive pathogens e2025-01-01T00:00:00Z2025 Aug2026-05-01T03:23:44.817Z2026-05-01T03:11:25.928ZS-EPMC124682734100271310.3390/diseases13090277